Global brokerage firm Nomura has initiated coverage on the newly listed Anthem Biosciences with a ‘Buy’ rating and a target price of Rs 740 for December 2026, implying an upside of 18% from current levels.The initiation comes despite the stock falling 22.4% over the past three months since listing in July 2025. Nomura believes the […]
